Literature DB >> 2191820

Formation of active metabolites of psychotropic drugs. An updated review of their significance.

S Caccia1, S Garattini.   

Abstract

Most of the currently available psychotropic drugs form 1 or more active metabolites during in vivo biotransformation in humans and/or animals. In some cases these metabolites are rapidly conjugated and excreted, but in others they attain blood and/or brain concentrations within the same range as, or even higher than, those of the parent drug, thus being potential biologically active compounds. The formation of metabolites with their own biological activity in addition to that of the parent compound may result in a complex situation where different chemical species participate in the final effects. These chemical species may have different pharmacokinetic properties of distribution and clearance. They may act by similar mechanisms, by different mechanisms or even antagonistically. The formation of active metabolites may be important not only for the therapeutic outcome but also for explaining the toxicity of particular drugs. The examples given, although limited, provide evidence that studies on drug metabolites are essential for an understanding of the mechanism of action of psychotropic drugs, and for extrapolating pharmacological and toxicological findings from animals to humans. The development of any new psychotropic agent requires knowledge of the pharmacology and toxicology of all active species as well as their pharmacokinetic profile, including the extent to which they reach the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2191820     DOI: 10.2165/00003088-199018060-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  100 in total

1.  Different effects of intracerebral and systemic administration of buspirone in the forced swimming test: involvement of a metabolite.

Authors:  L Cervo; G Grignaschi; R Samanin
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

Review 2.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

3.  Case report of withdrawal dyskinesia associated with amoxapine.

Authors:  I Lesser
Journal:  Am J Psychiatry       Date:  1983-10       Impact factor: 18.112

Review 4.  Considerations of toxicologic interactions in developing new chemicals.

Authors:  C F Wilkinson; M Murray
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

Review 5.  Genetic mechanisms controlling the induction of polysubstrate monooxygenase (P-450) activities.

Authors:  D W Nebert; H J Eisen; M Negishi; M A Lang; L M Hjelmeland; A B Okey
Journal:  Annu Rev Pharmacol Toxicol       Date:  1981       Impact factor: 13.820

Review 6.  Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-03       Impact factor: 9.546

7.  Amoxapine: neuroleptic as well as antidepressant?

Authors:  B M Cohen; P Q Harris; R I Altesman; J O Cole
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

8.  Tianeptine and its main metabolite pharmacokinetics in chronic alcoholism and cirrhosis.

Authors:  R J Royer; M J Royer-Morrot; F Paille; D Barrucand; J Schmitt; R Defrance; C Salvadori
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

9.  Carbon radicals in the metabolism of alkyl hydrazines.

Authors:  P R Ortiz de Montellano; O Augusto; F Viola; K L Kunze
Journal:  J Biol Chem       Date:  1983-07-25       Impact factor: 5.157

10.  Bupropion in depression. II. The role of metabolites in clinical outcome.

Authors:  R N Golden; C L De Vane; S C Laizure; M V Rudorfer; M A Sherer; W Z Potter
Journal:  Arch Gen Psychiatry       Date:  1988-02
View more
  11 in total

1.  Voriconazole and fluconazole increase the exposure to oral diazepam.

Authors:  Teijo I Saari; Kari Laine; Leif Bertilsson; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2007-08-04       Impact factor: 2.953

Review 2.  Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

3.  Single and multiple dose pharmacokinetics of etizolam in healthy subjects.

Authors:  C Fracasso; S Confalonieri; S Garattini; S Caccia
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  R J Milne; K L Goa
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 5.  Biotransformation of post-clozapine antipsychotics: pharmacological implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

6.  Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms.

Authors:  S Caccia; S Confalonieri; G Guiso; P Bernasconi; A Cagnotto; M Skorupska; T Mennini
Journal:  Psychopharmacology (Berl)       Date:  1994-08       Impact factor: 4.530

Review 7.  Drug therapy for geriatric depression.

Authors:  R Bressler; M D Katz
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 8.  Pharmacotherapy of insomnia: practice and prospects.

Authors:  J Dingemanse
Journal:  Pharm World Sci       Date:  1995-05-26

9.  Propranolol does not alter flutoprazepam kinetics and metabolism in the rat.

Authors:  I Conti; S Sarati; S Caccia
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

10.  The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.

Authors:  Pierre Baumann; Sven Ulrich; Gabriel Eckermann; Manfred Gerlach; Hans-Joachim Kuss; Gerd Laux; Bruno Müller-Oerlinghausen; Marie Luise Rao; Peter Riederer; Gerald Zernig; Christoph Hiemke
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.